{"entity":{"id":"nct06639256","kind":"trial","name":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Test Product HY07121 in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","summary":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06639256 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 258 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-05. Interventions recorded: Test Product HY07121.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06639256","url":"https://clinicaltrials.gov/study/NCT06639256"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06639256","phase":"1/2","setting":"An Open-label, Multiple-center, Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","enrolled":258,"outcomes":[]},"route":"/trials/nct06639256/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}